Navigation Links
NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD

NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD -- NESS ZIONA, Israel, November 9, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD


NESS ZIONA, Israel, November 9, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

Nicotinic brain circuitry has previously been shown to be involved in a variety of neurological diseases and disorders and, consequently, nicotinic receptors are the target of several agonist drugs under development. Nicotine, however, has had limited potential as a drug because its repeated use downregulates the actions of the nicotinic receptors. Based on pre-clinical studies, ND0801 is believed to work by preventing the desensitization of nicotinic receptors (contributing to nicotine addiction) that otherwise occurs as a result of repeat nicotine applications. The company hopes that, should it overcome the desensitization of nicotine effects, ND0801 may be beneficial in the treatment of cognitive and other central nervous system dysfunctions.

This Phase 2a study, conducted at two centers in Israel, is planned to enroll 45 ADD/ADHD patients. The trial will examine the safety, tolerability and optimal therapeutic dose of ND0801, and will evaluate the cognitive improvement in these subjects following treatment with ND0801, using standard cognition scale tests.

"The start of this clinical study with ND0801 is a major milestone for NeuroDerm. It marks the entry into clinical development of the company's second, innovative product, for the treatment of cognitive impairment," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "Nicotine is believed to have great potential for the treatment of many diseases. We hope that ND0801 might become the first patch to overcome the desensitization of nicotinic receptors, thereby offering an exciting new treatment option in CNS diseases."

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations and/or combinations of well established drugs to achieve a new clinical effect or improved clinical benefit. The company's clinical stage products include ND0611, a skin patch for the treatment of Parkinson's disease and ND0801, for the treatment of cognitive dysfunctions in ADD/ADHD and other CNS diseases. Other products for the treatment of various CNS diseases are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact: Oded S. Lieberman, PhD MBA, Chairman & CEO Tel.: +972-8-946 2729; Cell: +1-617-517 6077

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
2. American Regent Initiates Voluntary Recall of Magnesium Sulfate Injection, USP 50% (25 grams/50 mL), 50mL Single Dose Vial Lot # 0491
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
5. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
8. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
9. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
10. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
11. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
(Date:11/25/2015)... Research and Markets ( ) has announced the ... to 2020" report to their offering. ... the total market share in 2014. The market for ... to growth at the highest CAGR between 2015 and ... fast growing water, industrial gas treatment, pharmaceutical, and food ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... hands of philanthropic seniors, is resulting in a way for homeless people to ... in Schaumburg have launched a new initiative whereby they are repurposing plastic bags ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have ... to winners of the Create Real Impact awards. California Casualty is proud ... stem the tide of distracted and reckless driving, the number one killer of young ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... November 24, 2015 , ... ThirdLove, the fast-growing bra company ... early, offering 40% off select bras and underwear styles, now through Saturday, November ... fit technology and the latest fashion, quickly becoming the next generation of luxury ...
(Date:11/24/2015)... ... November 24, 2015 , ... The hospitals and ... several aspects of orthopedic care. They have received recognition for excellence from various ... care. , Becker's Hospital Review selected hospitals for inclusion based on national ...
Breaking Medicine News(10 mins):